Colef

OIPE ARNOLD & PORTER LLP

MAR 2-3 2007

202.942.5000 202.942.5999 Fax

555 Twelfth Street, NW Washington, DC 20004-1206

March 23, 2007

Attn: Certificate of Corrections Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent No. US 7,125,907 B2

Issued: June 24, 2007 Title: Thiolactones

Patentees: Barbara S. SLUSHER et al.

Attorney Docket No.: 20595.171

Certificate

MAR 2 8 2007

of Correction

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- 1. a Request for Certificate of Correction Under 37 C.F.R. §§ 1.322 & 1.323;
- 2. a Certificate of Correction (Form PTO/SB/44) (3 pages); and
- 3. a return postcard.

Please stamp the attached postcard with the filing date of these documents and return it to our courier.

Patentees request that the following fee be charged to Deposit Account No. 50-2387 referencing docket number P30691US01:

\$ 100.00 certificate of correction fee

In the event that extensions of time beyond those petitioned for herewith are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. Patentees do not believe any fees, other than the above (\$100), are due in conjunction with this filing. However, if any additional fees are required in the present application, including any fees for extensions of time, then the Commissioner is hereby authorized to charge such fees to Arnold & Porter LLP Deposit Account No. 50-2387 referencing matter number P30691US01.

Respectfully submitted,

Suet M. Chong (Reg. No. 38,104)

MAR 2 8 2007

Enclosures



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent of:

Confirmation No.: 8933

Barbara S. SLUSHER et al.

Art Unit:

1626

Patent No.:

US 7,125,907 B2

Examiner:

Susannah L. Chung

Issued:

(based on US 09/009,846) October 24, 2006

Atty. Docket:

20595.171

For:

Thiolactones

Request for Certificate of Correction Under 37 C.F.R. §§ 1.322 & 1.323

Attn: Certificate of Corrections Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.322 and 1.323, Patentees hereby request that a Certificate of Correction be issued reflecting the following changes.

At Column 32, lines 20-58, please amend claim 1 to read as follows:

1. A compound of formula I

$$X$$
 CO_2H
 X
 O
 Z
 S

or a pharmaceutically acceptable equivalent, an optical isomer or a mixture of isomers of the compound, wherein:

MAR 2 8 2007

X is C₁-C₄ alkylene, C₂-C₄ alkenylene, C₂-C₄ alkynylene, C₃-C₈ cycloalkylene, C₅-C₇ cycloalkenylene or Ar, wherein the alkylene, alkenylene, alkynylene, cycloalkylene or cycloalkenylene is unsubstituted or substituted with one or more substituent(s);

Ar is a bivalent aryl or heteroaryl radical that is unsubstituted or substituted with one or more substituent(s); and

 R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, C_1 - C_4 alkyl or C_2 - C_4 alkenyl, wherein the alkyl or alkenyl is unsubstituted or substituted with one or more substituent(s). [[;]]

R⁷ is hydrogen, phenyl, phenylethyl or benzyl wherein the phenyl, phenylethyl or benzyl is unsubstituted or substituted with one or more substituent(s); and

 R^8 , R^9 , R^{10} and R^{11} are independently hydrogen, carboxy, hydroxy, halo, nitro, eyano, C_1 - C_4 alkyl or C_1 - C_4 alkoxy;


provided that when the compound is of formula I, L is a bond and X is ethyl, then Y is not -CR³R⁴-.

At Column 33, lines 8-11, please amend claim 5 to read as follows:

5. A method of treating peripheral neuropathy, comprising administering to a mammal in need of such **inhibition**, treatment, an effective amount of a compound of formula I of claim 1.

At Column 33, line 12, through Column 34, line 21, please amend claim 6 to read as follows:

- 6. A pharmaceutical composition comprising:
 - (i) an effective amount of a compound of formula I



$$X$$
 CO_2H
 X
 CO_2H
 X
 CO_2H
 X

or a pharmaceutically acceptable equivalent, an optical isomer or a mixture of isomers of the compound, wherein:

X is C₁-C₄ alkylene, C₂-C₄ alkenylene, C₂-C₄ alkynylene, C₃-C₈ cycloalkylene, C₅-C₇ cycloalkenylene or Ar, wherein the alkylene, alkenylene, alkynylene, cycloalkylene or cycloalkenylene is unsubstituted or substituted with one or more substituent(s);

L is a bond,
$$-CR^1R^2$$
-, $-O$ -, $-S$ -, $-SO_2$ - or $-NR^1$ -;
Y is $-CR^3R^4$ —;
Z is $-(CR^5R^6)_n$ -;
n is 2;

Ar is a bivalent aryl or heteroaryl radical that is unsubstituted or substituted with one or more substituent(s);

 R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, C_1 - C_4 alkyl or C_2 - C_4 alkenyl, wherein the alkyl or alkenyl is unsubstituted or substituted with one or more substituent(s); <u>and</u>

R⁷ is hydrogen, phenyl, phenylethyl or benzyl wherein the phenyl, phenylethyl or benzyl is unsubstituted or substituted with one or more substituent(s); and

R⁸, R⁹, R¹⁰ and R¹¹ are independently hydrogen, earboxy, hydroxy, halo, nitro, eyano, C₁-C₄-alkyl or C₁-C₄-alkoxy; and

(ii) a pharmaceutically acceptable carrier.

Patentees note that the correction to Claim 5 and the correction to Claim 6 at Column 34, line 6 (Y is -CR³R⁴___), are necessitated as a result of Patent Office errors in the printing of U.S.

Patent No. 7,125,907. Support for the correction to Claim 5 may be found on page 3 of the Supplemental Action attached to the Corrected Notice of Allowance and Fee(s) Due, mailed April 20, 2006. Support for the correction to Claim 6 at Column 34, line 6, may be found in the claims as originally filed.

Patentees note that the corrections to Claim 1 and the corrections to Claim 6 at Column 34, lines 10-20 are requested to remove text pertaining to chemical formulas that were removed previously from the claims. Authorization to charge fees associated with this request are given in the accompanying transmittal letter.

The Commissioner is invited to contact the Patentee's undersigned representative at 202-942-5849 t address any unresolved issues remaining in this patent.

Respectfully submitted,

Suet M. Chong (Reg. Atty. No. 38,104)

Date: March 23, 2007

ARNOLD & PORTER LLP 555 12th Street, N.W. Washington, D.C. 20004 (202) 942-5000 telephone (202) 942-5999 facsimile

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 3

PATENT NO

US 7,125,907 B2

APPLICATION NO.:

10/791,278

ISSUE DATE

October 24, 2006

INVENTOR(S)

Barbara S. SLUSHER et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 32, lines 20-58, please replace claim 1 with claim 1 as follows:

1. A compound of formula I

or a pharmaceutically acceptable equivalent, an optical isomer or a mixture of isomers of the compound, wherein:

X is C_1 - C_4 alkylene, C_2 - C_4 alkenylene, C_2 - C_4 alkynylene, C_3 - C_8 cycloalkylene, C_5 - C_7 cycloalkenylene or Ar, wherein the alkylene, alkenylene, alkynylene, cycloalkylene or cycloalkenylene is unsubstituted or substituted with one or more substituent(s);

L is a bond, $-CR^1R^2$ -, -O-, -S-, $-SO_2$ - or $-NR^1$ -;

Y is -CR³R⁴-:

Z is - $(CR^5R^6)_{n}$ -;

n is 2;

Ar is a bivalent aryl or heteroaryl radical that is unsubstituted or substituted with one or more substituent(s); and

R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, C₁-C₄ alkyl or C₂-C₄ alkenyl, wherein the alkyl or alkenyl is unsubstituted or substituted with one or more substituent(s).

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Arnold & Porter LLP Attn: IP Docketing 555 Twelfth Street, N.W. Washington, D.C. 20004-1206

1 2 8 2007

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 3

PATENT NO

US 7,125,907 B2

APPLICATION NO.:

10/791,278

ISSUE DATE

October 24, 2006

INVENTOR(S)

Barbara S. SLUSHER et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 33, lines 8-10, please replace claim 5 with claim 5 as follows:

5. A method of treating peripheral neuropathy, comprising administering to a mammal in need of such treatment, an effective amount of a compound of formula I of claim 1.

At Column 33, line 12, through Column 34, line 21, please replace claim 6 with claim 6 as follows:

- 6. A pharmaceutical composition comprising:
 - (i) an effective amount of a compound of formula I

$$X$$
 X
 X
 Y
 Z
 S

or a pharmaceutically acceptable equivalent, an optical isomer or a mixture of isomers of the compound, wherein:

X is C_1 - C_4 alkylene, C_2 - C_4 alkenylene, C_2 - C_4 alkynylene, C_3 - C_8 cycloalkylene, C_5 - C_7 cycloalkenylene or Ar, wherein the alkylene, alkenylene, alkynylene, cycloalkylene or cycloalkenylene is unsubstituted or substituted with one or more substituent(s);

L is a bond, $-CR^1R^2$ -, -O-, -S-, $-SO_2$ - or $-NR^1$ -;

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Arnold & Porter LLP Attn: IP Docketing 555 Twelfth Street, N.W. Washington, D.C. 20004-1206

11 12 2 8 2007

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chlef Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 3 of 3

PATENT NO

US 7,125,907 B2

APPLICATION NO.:

10/791,278

ISSUE DATE

October 24, 2006

INVENTOR(S)

Barbara S. SLUSHER et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Column 33, line 12, through Column 34, line 21, please replace claim 6 with claim 6 as follows (cont'd):

Y is -CR³R⁴-:

Z is $-(CR^5R^6)_{0}$ -;

n is 2:

Ar is a bivalent aryl or heteroaryl radical that is unsubstituted or substituted with one or more substituent(s);

R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, C₁-C₄ alkyl or C₂-C₄ alkenyl, wherein the alkyl or alkenyl is unsubstituted or substituted with one or more substituent(s); and

(ii) a pharmaceutically acceptable carrier.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Arnold & Porter LLP Attn: IP Docketing 555 Twelfth Street, N.W. Washington, D.C. 20004-1206

MAR 2 8 2007/

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.